SUMMIT, N.J., June 19 /PRNewswire-FirstCall/ -- C

Celgene said Friday its oral cancer drug Revlimid has received a positive recommendation in Europe. The European Medicines Agency has advised approval of the drug for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

SUMMIT, N.J., March 23 /PRNewswire-FirstCall/ --